Two Sigma Investments LP Acquires 260,318 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Two Sigma Investments LP boosted its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 41.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 891,279 shares of the company's stock after buying an additional 260,318 shares during the quarter. Two Sigma Investments LP owned approximately 0.39% of Gossamer Bio worth $806,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Octagon Capital Advisors LP grew its position in shares of Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock valued at $16,599,000 after purchasing an additional 9,162,117 shares during the last quarter. Alyeska Investment Group L.P. grew its position in shares of Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock valued at $7,968,000 after purchasing an additional 3,041,058 shares during the last quarter. Silverarc Capital Management LLC grew its position in shares of Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after purchasing an additional 526,495 shares during the last quarter. Monaco Asset Management SAM grew its position in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after purchasing an additional 1,520,721 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of Gossamer Bio by 14.6% in the fourth quarter. Millennium Management LLC now owns 3,586,067 shares of the company's stock valued at $3,244,000 after purchasing an additional 457,179 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Price Performance

Shares of GOSS stock traded up $0.04 during trading on Wednesday, hitting $1.29. The company had a trading volume of 1,670,879 shares, compared to its average volume of 1,551,000. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market capitalization of $293.22 million, a P/E ratio of -4.03 and a beta of 1.85. The stock's 50-day moving average price is $1.04 and its 200 day moving average price is $1.04. Gossamer Bio, Inc. has a one year low of $0.51 and a one year high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. Equities analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Finally, The Goldman Sachs Group upped their target price on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, May 16th.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.